文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

长效卡博特韦/利匹韦林在HIV病毒学抑制者中的真实世界有效性与停药预测因素:Icona队列数据

Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

基于Icona队列583例基线HIV-RNA<50拷贝/mL并启动长效卡博特韦/利匹韦林治疗的HIV感染者,采用Kaplan-Meier法与Cox回归分析停药和病毒学失败。1年病毒学失败累积概率为1.2%(95%CI 0.5%-3.0%),1年停药累积概率为11.4%(95%CI 8.6%-14.9%),停药主要因毒性/不良事件(73.2%);多因素分析显示异性性行为与静脉吸毒较MSM为停药的显著危险因素。

要点

  • 真实世界中长效卡博特韦/利匹韦林短期病毒学失败率低,1年累积概率1.2%。
  • 1年停药累积概率11.4%,主要原因为毒性/不良事件(73.2%)。
  • 异性性行为与静脉吸毒者较MSM停药风险显著升高。

核心结论

  • 长效卡博特韦/利匹韦林在真实世界中短期有效性好,病毒学失败率低,但因毒性或不良事件停药的概率不容忽视。

研究设计与样本

  • Icona队列分析,纳入所有启动长效卡博特韦/利匹韦林且HIV-RNA<50拷贝/mL的HIV感染者,共583例。
  • 采用Kaplan-Meier法估计停药与病毒学失败时间,Cox回归模型按年龄、性别、HIV传播途径校正并按中心分层。

主要发现

  • 共观察到6例VF50,1年病毒学失败累积概率1.2%(95%CI 0.5%-3.0%)。
  • 1年停药累积概率11.4%(95%CI 8.6%-14.9%),主要因毒性/不良事件(73.2%)。
  • 4例接受基因型耐药检测的VF50者中,利匹韦林耐药相关突变3/4、卡博特韦耐药相关突变4/4。
  • 多因素分析中,与MSM相比异性性行为和静脉吸毒为停药的显著危险因素。

关键数值与推荐

  • 病毒学失败定义:连续两次HIV-RNA>50拷贝/mL,或一次>1000拷贝/mL后换用抗逆转录病毒治疗。
  • 1年病毒学失败累积概率1.2%(95%CI 0.5%-3.0%),1年停药累积概率11.4%(95%CI 8.6%-14.9%)。

临床怎么用

  • 对病毒学抑制的HIV感染者,长效卡博特韦/利匹韦林可作为维持治疗选择,但需关注毒性/不良事件导致的停药。
  • 启动前及随访中应关注传播途径相关因素(异性性行为、静脉吸毒)对停药风险的影响。

局限性

  • 为观察性队列真实世界数据,随访为短期,病毒学失败事件数少(6例)。
  • 基因型耐药检测仅在部分VF50者中完成(4例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Phase 3 studies have shown long-acting (LA) cabotegravir/rilpivirine to be effective and tolerable as maintenance therapy in people with HIV (PWH). However, real-life data on their effectiveness are limited. METHODS: All PWH enrolled in the Icona Cohort who started LA cabotegravir/rilpivirine with HIV-RNA < 50 copies/mL were included. Times to treatment discontinuation (TD) and to virological failure (VF50, two consecutive HIV-RNA >50 copies/mL or one >1000 copies/mL followed by ART switch) were estimated by the Kaplan-Meier method. Cox regression models, adjusted for age, sex and mode of HIV transmission and stratified by the centre, were employed. RESULTS: Overall, 583 PWH started LA cabotegravir/rilpivirine. Six VF50 were observed, with a 1 year estimated cumulative probability of virological failure of 1.2% (95% CI, 0.5%-3.0%). Resistance-associated mutations for rilpivirine and cabotegravir were detected in 3/4 and 4/4 participants with VF50, respectively, for which the genotypic resistance test was performed.The 1 year cumulative probability of TD was 11.4% (95% CI, 8.6%-14.9%), mainly caused by toxicity/adverse events (73.2%). Multivariable analysis identified heterosexual intercourse and IV drug use as significant risk factors for TD compared with MSM. CONCLUSIONS: This analysis demonstrated the short-term effectiveness of cabotegravir/rilpivirine in a real-life setting showing minimal incidence of virological failure but a notable probability of discontinuation due to toxicity or adverse events.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Gagliardini R, De Benedittis S, Tavelli A, et al. Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort. J Antimicrob Chemother. 2025. PMID: 40570134. doi:10.1093/jac/dkaf184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。